Dechert advised Laboratoire HRA Pharma on the deal.
Laboratoire HRA Pharma, a portfolio company jointly backed by European private equity group Astorg Partners and Goldman Sachs Merchant Banking Division, acquired the global rights to the Mederma brand from Merz Pharmaceuticals GmbH.
HRA Pharma is a fast-growing, innovative global consumer healthcare company.
Mederma is a market leader in scar care and offers a range of over-the-counter products across the scar care, stretch marks and skin care categories.
With the addition of Mederma® to its portfolio, HRA Pharma now has a solid consumer healthcare platform in the US and intends to pursue its development combining ambitious organic growth, launches of innovative Rx to OTC switches, and other targeted acquisitions.
Subject to customary closing conditions and regulatory approvals, the transaction is expected to close within the second quarter of 2019. The terms of this agreement, which includes the sale of the Mederma®, Mederma® AG, Eldertonic® and Nu-Iron® products, were not disclosed.
The Dechert team on this transaction included a London-based team led by partner Ross Allardice (Picture), with senior associate Tony Brown and associates Daniel Mansfield and David Nicholls, a Paris-based team led by partners Alain Decombe and Melanie Thill-Tayara and national partners Laurence Bary and Marie Fillon with associate Louis de Chezelles, a Munich-based team led by partner Giovanni Russo and National Partner Dr. Karl von Rumohr and a Washington-based team led by partner Craig Falls and counsel Beverly Ang.
Involved fees earner: Ross Allardice – Dechert; Beverly Ang – Dechert; Laurence Bary – Dechert; Tony Brown – Dechert; Louis de Chezelles – Dechert; Alain Decombe – Dechert; Craig Falls – Dechert; Marie Fillon – Dechert; Dan Mansfield – Dechert; David Nicholls – Dechert; Giovanni Russo – Dechert; Mélanie Thill-Tayara – Dechert; Karl von Rumohr – Dechert;
Law Firms: Dechert;
Clients: HRA Pharma;